MEDIPOST said on the 4th that its cord blood bank brand, Celltree, launched the country's first "cord tissue-derived stem cell storage" service.
Cord tissue is a life resource that can be collected from the "umbilical cord," which connects the fetus and the placenta. Many overseas cord blood banks store cord tissue along with cord blood to prepare for treating a wider range of diseases in the future.
In Korea, expectations have grown for activating treatments using stem cells following the recent revision of the "Act on the Safety and Support of Advanced Regenerative Medicine and Advanced Biopharmaceuticals (Advanced Regenerative Bio Act)." If cord blood and cord tissue are stored together, a large number of stem cells can be secured, potentially expanding the scope of future clinical applications and treatment opportunities.
Celltree established an integrated storage system that encompasses cord tissue, reflecting market changes and customer demand. A MEDIPOST official said, "With changes in overseas markets and the recent revision of the Advanced Regenerative Bio Act in Korea, activation of autologous stem cell treatments is anticipated," adding, "With the introduction of this cord tissue-derived stem cell storage service, we will do our best to help expectant parents in Korea prepare for treating a variety of diseases in the future."